Patents
Methods for promoting growth of bone, ligament, and cartilage using zvegf4
Patent Number: 6866991This patent describes the use of zvegf3, a platelet derived growth factor homologue for expansion of various stem cells, including bone marrow stem cells.
Inventors: Gilbertson, Debra G. (Seattle, WA); Hart, Charles E. (Woodinville, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Monday May 3rd, 1999
Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
Patent Number: 6866843This patent teaches extraction of pancreatic stem cells based on expression of nestin...expansion of the cells into islet-like cells...and transplantation of the cells for treatment of diabetes. The problem is how much expansion can one achieve? Since there is a SEVERE shortage of donor pancreas'. The other problem, of course, is the need for immune suppression.
Inventors: Habener, Joel F. (Newton Centre, MA); Zulewski, Henryk (Basel, CH); Abraham, Elizabeth (Quincy, MA); Vallejo, Mario (Madrid, ES); Faustman, Denise L. (Weston, MA); Thomas, Melissa K. (Boston, MA)
Assignee: Viacell, Inc. (Charlestown, MA
Date of First Priority Issue: Monday December 6th, 1999
Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
Patent Number: 6866842This patent teaches the use of skeletal myoblast, muscle stem cells, for treating urinary incontinence. The cells may be used without modification, or may be genetically engineered to express therapeutic genes. Examples of therapeutic genes include nerve growth factor, nitric oxide, etc.
Inventors: Chancellor, Michael B. (Pittsburgh, PA); Huard, Johnny (Wexford, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Friday May 1st, 1998
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
Patent Number: 6864235The ability of cells to respond to danger signals is associated with how the host will respond to injury in general. This patent is based around observations that cellular injury is associated with upregulation of certain danger signal associated molecules, which the inventors call "transition molecules". This is most likely why the name of one of the companies that the inventors established...
Inventors: Turley, Eva A. (Toronto, CA); Cruz, Tony F. (Etobicoke, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday April 1st, 1999
Regeneration and augmentation of bone using mesenchymal stem cells
Patent Number: 6863900Inventors: Kadiyala, Sudhakar (Baltimore, MD); Bruder, Scott P. (Owings Mills, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday April 19th, 1996
Neuroprotective composition and uses thereof
Patent Number: 6858646Oxidative stress plays a very important role in the ability of stem cells to survive. Specifically, stem cells prefer to reside in areas of relative hypoxia, and are particularly senstive to oxidative stress. This patent teaches that use of pyruvate, and other antioxidants in order to protect neurons, and stem cells of neurons, from damage. This patent may be used to treat, for example...
Inventors: Paquin, Joanne (Montreal, CA); Mateescu, Mircea-Alexandru (Montreal, CA); De Grandpre , Eric (Joliette, CA)
Assignee: Universite du Quebec a Montreal (Montreal, CA)
Date of First Priority Issue: Wednesday May 5th, 1999
Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
Patent Number: 6852534At first glance this patent seems extremely simple and maybe even obvious. Essentially it teaches the use of counting of leukocytes from a hematopoietic stem cell graft so has to know how many cells to transplant for hematopoietic reconstitution. The invention is however very important in areas like cord blood stem cell transplants where it is very difficult to actually quantify the number...
Inventors: Wernet, Peter (Dusseldorf, DE); Kogler, Gesine (Dusseldorf, DE); Fischer, Johannes (Neuss, DE)
Assignee: Kourion Therapeutics GmbH (Duesseldorf, DE)
Date of First Priority Issue: Friday November 3rd, 2000
Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
Patent Number: 6858583Hematopoietic stem cells are sensitive to chemotherapy and radiation therapy. Accordingly, hematopoietic stem cells are one of the first cell types to be negatively affected by cancer therapy. One of the reasons that hematopoietic stem cells are destroyed is due to the fact that at some level, they are proliferating constantly. Now, the early primitive hematopoietic stem cells usually are...
Inventors: Tsyrlova, Irena (Gaithersburg, MD); Wolpe, Stephen D. (Rockville, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday March 31st, 1993
Methods and compositions for healing heart wounds
Patent Number: 6852706This patent teaches activation of cardiac healing processes through reducing levels of thyroid hormone. This patent seems to depart substantially from the common notion that thyroid hormone is actually beneficial for the heart. For example, it is published that reducing thyroid hormone by administration of propylthiouracil actually leads to cardiac atrophy, angina and general deterioration (Tang...
Inventor: Heber-Katz, Ellen (Philadelphia, PA)
Assignee: The Wistar Institute (Philadelphia, PA)
Date of First Priority Issue: Wednesday March 22nd, 2000
Transgenic circulating endothelial cells
Patent Number: 6852537This patent covers the expansion of endothelial cells by growing on collagen-1 coated plates in the combination of various growth factors such as FGF, VEGF, and IGF. Additionally, numerous culture conditions for endothelial expansion are disclosed. The abstract of the patent discribes the use of endothelial cells for gene therapy, but not the claims. The disclosure also describes how...
Inventors: Hebbel, Robert P. (North Oaks, MN); Lin, Yi (St. Paul, MN); Lollar, John S. (Decatur, GA)
Assignee: Regents of the University of Minnesota Emory University (Atlanta, GA)
Date of First Priority Issue: Tuesday November 24th, 1998